Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.65 USD
+0.47 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Deciphera Pharmaceuticals, Inc. (DCPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.89 | $34.00 | $16.00 | 82.58% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Deciphera Pharmaceuticals, Inc. comes to $25.89. The forecasts range from a low of $16.00 to a high of $34.00. The average price target represents an increase of 82.58% from the last closing price of $14.18.
Analyst Price Targets (9 )
Broker Rating
Deciphera Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on nine recommendations.
Of the 10 recommendations deriving the current ABR, eight are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 77.78%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.60 | 1.60 | 1.67 | 1.67 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/22/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
2/7/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/7/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
12/15/2023 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
10/25/2023 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $25.89 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.55 |